Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily
- 1 January 1997
- journal article
- review article
- Published by Begell House in Critical Reviews™ in Neurobiology
- Vol. 11 (2-3) , 167-239
- https://doi.org/10.1615/critrevneurobiol.v11.i2-3.40
Abstract
The calcitonin gene peptide superfamily consists of calcitonin (CT), calcitonin gene-related peptide (CGRP), and amylin. CT and CGRP derive from the CT/CGRP gene, which is encoded on chromosome 11. Alternative splicing of the primary RNA transcript leads to the translation of CGRP and CT. peptides in a tissue-specific manner. CGRP (a 37-amino-acid neuropeptide) and its receptors are widely distributed in the body, and it is the most potent endogenous vasodilatory peptide discovered so far. CT (a 32-amino-acid peptide) is, however, a hormone primarily involved in protecting the skeleton during periods of ''calcium stress'' such as growth, pregnancy, and lactation. CT derives from the C cells of the thyroid gland and is the most potent peptide inhibitor of osteoclast-mediated bone resorption. Therefore, treatment with CT is highly effective for conditions associated with increased bone turnover such as Pager's disease, osteoporosis, Sudeck's atrophy, and hypercalcemia. Amylin (a 37-amino-acid peptide) is generated from a gene located on chromosome 12 (thought to be an evolutionary duplication of chromosome 11) and shares 46% amino acid sequence homology with CGRP and 20% with human CT. Amylin is predominantly located in the beta cells of the islets of the pancreas and may be involved in the pathogenesis of type IT diabetes by deposition as amyloid within the pancreas, leading to beta cell destruction. Adrenomedullin, a recently discovered 52-amino-acid vasoactive peptide from adrenal tissue, shares 24% homology with CGRP and is also a member of this superfamily of peptides. A portion of the B-chain of insulin is strongly homologous to these four peptides. Not only does adrenomedullin (13-52) show 24% amino acid homology with CGRP, it also has a biological activity profile similar to that of CGRP. CGRP, CT, and amylin are related to the insulin gene superfamily of peptides, which may all have diverged from a common ancestral gene during evolution. When the crystallographic and nuclear magnetic resonance-based molecular modeling of the three-dimensional structure of CGRP, CT, amylin, and adrenomedullin peptides and their receptors is available, it will lead to a greater understanding of the involvement of this family of peptides in pathophysiology. Together, CGRP, CT, amylin and adrenomedullin have overlapping biological effects owing to their structures and cross-reactivity between receptors. I propose that CT, CGRP, adrenomedullin, and amylin belong to a family of G-protein-coupled receptors (an ''insulin superfamily'' of peptides) and therefore share some of the characteristics of insulin, such as growth factor-like effects, and possible interaction at insulin receptor sites as an antagonist.Keywords
This publication has 215 references indexed in Scilit:
- Calcium-Regulating Hormones in Essential HypertensionAnnals of Internal Medicine, 1986
- Long-Term Estrogen Replacement Therapy Prevents Bone Loss and FracturesAnnals of Internal Medicine, 1985
- Effect of Calcitonin and Glucocorticoids in Combination on the Hypercalcemia of MalignancyAnnals of Internal Medicine, 1980
- WHISKY: A NEW PROVOCATIVE TEST FOR CALCITONIN SECRETIONActa Endocrinologica, 1976
- OBSERVATIONS ON SMALL GRANULE CELLS IN ADULT HUMAN BRONCHIAL EPITHELIUM AND IN CARCINOID AND OAT CELL TUMORS1976
- An Improved Method for the Biological Assay of ThyrocalcitoninEndocrinology, 1967
- Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroidJournal of Clinical Pathology, 1966
- Calcitonin Production and the Mitochondrion-Rich Cells of the Dog ThyroidNature, 1964
- Evidence for Calcitonin—A New Hormone from the Parathyroid That Lowers Blood CalciumEndocrinology, 1962
- MEDULLARY (SOLID) CARCINOMA OF THE THYROID—A CLINICOPATHOLOGIC ENTITY*Journal of Clinical Endocrinology & Metabolism, 1959